ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures
ResMed Inc. (RMD) reported a 9% revenue increase to $1.5B in Q4 2026, driven by strong demand for sleep devices. RBC Capital upgraded RMD to Outperform, raising its price target to $262. However, the company faces risks from competition, lower-than-expected 2027 guidance, and a ventilator recall. Hedge funds maintained interest, with some increasing stakes.
How this was made
The 30-second read
Why it matters
Earnings and guidance release provide fresh data for valuation models; upgrade adds a positive angle.
Market read
ResMed's earnings and guidance update are material for investors in medical‑device equities.
What to watch
Potential upside from recurring accessory revenue and long‑term market expansion.
Background
ResMed is a leading provider of obstructive sleep apnea (OSA) therapy devices, facing competition from Philips Respironics.
Ticker impact
ResMed reported Q4 FY2026 revenue up 9% YoY to $1.5B and issued FY2027 guidance below expectations, plus an upgrade and higher price target.
Potential short-term dip on guidance miss, followed by stabilization if upgrade gains traction.
Guidance shortfall is material, but the upgrade and recurring revenue narrative provide upside catalysts.
Market effects
Highlights competitive pressure in sleep‑apnea devices, especially from Philips Respironics re‑entry.
U.S. market focus; no immediate global ripple.
Reinforces demand growth in the broader medical device sector.
Counterpoint
Short sellers may target the stock on the guidance miss despite the upgrade.
Key entities
- AnalystRBC Capital Markets
Upgraded ResMed to Outperform and raised price target.
- CompetitorPhilips Respironics
Potential market re‑entry could pressure ResMed sales.
